Skip to main content
| News

TargImmune raises nearly 18 million Swiss francs

20.07.2021

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends to transfer its lead candidate to clinical development. The company develops immunotherapies for the targeted destruction of tumors.

TargImmune Therapeutics develops targeted immunotherapies that fight the tumor itself, alert the immune system and destroy neighboring tumor cells. The Basel-based company now intends to transfer its lead product candidate Tar001 to clinical development and can call upon proceeds raised from a financing round for this purpose, further details of which can be found in an article published by startupticker.ch. TargImmune raised a total of 17.7 million Swiss francs in the aforementioned financing round.

Based at the Technologiepark Basel, TargImmune is developing its drug using the company’s proprietary RNA platform. Clinical development is expected to begin in the second quarter of 2022. TargImmune also plans to file an application with the U.S. Food and Drug Administration with the aim of securing Investigational New Drug status.

However, CEO Esteban Pombo-Villar is set to leave his post and will in future work as Head of Technology for the Basel-based company, which was founded back in 2016. On August 16, 2021, Peter Braun will then take over management responsibility. He has 25 years of professional experience. Most recently, he worked for the Norwegian company Nordic Nanovector.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

How Moderna is growing in Switzerland
Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Sandoz decides on Basel for headquarters
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
University of Basel and RocketVax present new Covid vaccine
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
Rami Swiss and Elbit Systems now manufacturing in Jura
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest

Rami Swiss and Elbit Systems now manufacturing in Jura

The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...

Read More
Basel to become Europe’s Silicon Valley of biotech
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel to become Europe’s Silicon Valley of biotech

Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....

Read More
1 2 3 34

Do you have a question? We'd like to hear from you.